Kathleen O'ConnorView profile
Professor
Kathleen O'Connor is a Professor in the Department of Molecular and Cellular Biochemistry at the University of Kentucky, where she also serves as the Associate Director of Cancer Education in the Markey Cancer Center. She is a member of the Markey Cancer Center’s Cancer Research Priority Initiative and the Molecular and Cellular Oncology Research Program, as well as the UNITE Research Priority Area. Her interdisciplinary roles reflect her leadership in cancer research and education. Doctor of Philosophy, Case Western Reserve University, 1996 Bachelor of Science, James Madison University, 1988 Dr. O'Connor's research focuses on the molecular mechanisms of cancer progression, particularly how integrin receptors—especially α6β4—mediate signaling that drives carcinoma cell invasion. Her lab investigates the interplay between integrin signaling and cyclic AMP metabolism, Rho GTPase regulation, and the expression of pro-invasive genes such as autotaxin, S100A4, and EGFR ligands. This work has significant implications for understanding the aggressive behavior of cancers in the breast, colon, and pancreas. Her recent publications (2022–2025) highlight sustained contributions to cancer biology, with studies on integrin-mediated chemosensitization, cytoskeletal regulation of invasion, and social determinants of breast cancer outcomes. These works span disciplines including molecular oncology, cell signaling, and health disparities, reflecting a broad and impactful research portfolio. Scientific awards include: Distinguished Faculty Teaching Award, Nominee (2006) Wethington Excellence in Research Award (2013, 2014, 2017) Women in Medicine and Science Mentorship, Finalist (2018) Dr. O'Connor is actively involved in mentoring and training the next generation of scientists. She leads several funded initiatives, including the Markey STRONG Post-baccalaureate Program and a Diversity in Cancer Research Supplement from the American Cancer Society, aimed at increasing representation of underrepresented minorities in biomedical research. She is the Principal Investigator (PI) on multiple active grants, including projects focused on triple-negative breast cancer and chemotherapy optimization, funded by the American Cancer Society and the National Cancer Institute. Her work bridges basic science and translational applications, with collaborations across institutions and disciplines. She is embedded in a vibrant research ecosystem at the Markey Cancer Center, where she contributes to education, mentorship, and collaborative research networks aimed at combating cancer through innovative science and inclusive training programs.







